Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders
01 mai 2020 08h00 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today provided notice of a change in the location for its 2020 Annual Meeting of...
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
12 mars 2020 07h30 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 12, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and year...
Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma
05 mars 2020 07h00 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or “the company”) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its...